本研究之目的是分析腦轉移癌症病患接受直線加速器立體定位放射手術治療之治療結果與預後因子。資料收集從2003年4月到2007年7月接受直線加速器立體定位放射手術治療之腦轉移病患。本研究評估影響病患的預後因子分析包括年齡、性別、原始腫瘤位置、原始腫瘤控制、腦轉移病灶數量、和柯氏體能表現狀態(Karnofsky Performance Status, KPS)。34位接受立體定位放射手術之腦轉移病患，其年齡範圍爲42到81歲，中位數年齡爲61歲。立體定位放射手術的劑量範圍爲14至27.5Gy。存活時間範圍從3至49個月，中位數存活月爲18個月，一年存活率約爲61.8%，兩年存活率爲39.1%。男性腦轉移病患中位數存活月爲26個月，而女性到腦轉移病患中位數存活月爲11個月。在這回朔性研究中，我們發現性別、原始腫瘤控制和柯氏體能表現狀態對於接受直線加速器立體定位放射手術治療之腦轉移病患爲統計上有意義的預後因子。

The purpose of this study is to analyze the treatment outcome and prognosis factors of the cancer patients with brain metastases treated with linear accelerator (LINAC) based stereotactic radiosurgery (SRS). During the period between April 2003 and July 2007, thirty-four patients with brain metastases underwent LINAC-based SRS were included in this retrospective study. Theprognostic factors evaluated including: age, sex, primary tumor site, status of primary tumor control, the number of brain metastases, and Karnofsky Performance Status (KPS).Of the 34 patients, the median age was 61 years (range: 42-8 1 years). The range of SRS dose were 14Gy to 27.5 Gy. The median survival time was 18 months (range: 3-49 months). The 1-year survival rate was 61.8% and the 2-year survival rate was 39.1%. The median survival in male patients was 26 months, and the median survival in female patients was 11 months. In this study, we found that the sex, status of primary tumor control, and KPS are significant surrogates of prognosis.